• Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma...
    15 KB (1,447 words) - 06:28, 15 September 2024
  • Thumbnail for PD-1 and PD-L1 inhibitors
    non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment...
    35 KB (3,450 words) - 17:21, 27 September 2024
  • Thumbnail for Cancer immunotherapy
    was approved for medical use in the United States in September 2024. Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody...
    92 KB (12,353 words) - 07:41, 15 September 2024
  • Human Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab...
    38 KB (4,316 words) - 10:24, 26 August 2024
  • small cell lung cancer, hepatocellular carcinoma, metastatic melanoma Avelumab Bavencio Merck KGaA and Pfizer PD-L1 2017 Merkel cell carcinoma, urothelial...
    21 KB (2,093 words) - 02:41, 1 September 2024
  • Thumbnail for Programmed cell death protein 1
    BMS-936559 (Bristol Myers Squibb). Both atezolizumab (MPDL3280A, Roche) and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) target the similar PD-L1 receptor...
    39 KB (5,010 words) - 05:27, 17 August 2024
  • Thumbnail for Toni Choueiri
    work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic factors in...
    17 KB (1,497 words) - 16:35, 25 November 2023
  • Thumbnail for Merkel-cell carcinoma
    the U.S. Food and Drug Administration granted accelerated approval to avelumab, a PDL1 inhibitor, to treat adults and children above 12 years with metastatic...
    50 KB (5,542 words) - 17:33, 28 September 2024
  • breast cancer Tafamidis meglumine Foldrx Pharmaceuticals cardiomyopathy Avelumab EMD Serono advanced renal cell carcinoma Venetoclax AbbVie chronic lymphocytic...
    34 KB (180 words) - 22:09, 8 April 2024
  • Thumbnail for Renal cell carcinoma
    results in more progression of the cancer than pembrolizumab, axitinib and avelumab. In comparison to pembrolizumab and axitinib, it probably results in more...
    101 KB (10,959 words) - 10:41, 18 September 2024
  • Thumbnail for Bladder cancer
    nivolumab, and are inhibitors of programmed cell-death ligand 1 (PD-1). Avelumab, atezolizumab and durvalumab are inhibitors of PD-L1. Pembrolizumab probably...
    88 KB (8,969 words) - 20:03, 19 September 2024
  • Thumbnail for PD-L1
    trials. Clinically available examples include durvalumab, atezolizumab and avelumab. In normal tissue, feedback between transcription factors like STAT3 and...
    25 KB (3,052 words) - 15:34, 14 September 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    human Rhesus factor hemolytic disease of the newborn[citation needed] Avelumab Bavencio mab human PD-L1 Y cancer Axatilimab Niktimvo mab humanized CSF1R...
    136 KB (4,020 words) - 06:13, 27 September 2024
  • Thumbnail for Myasthenia gravis
    These checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, and durvalumab. From a total 5,898 patients who received...
    84 KB (8,872 words) - 10:43, 13 September 2024
  • (Gemtuzumab ozogamicin) Other Amivantamab Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab...
    12 KB (808 words) - 05:25, 15 September 2024
  • Thumbnail for Monoclonal antibody therapy
    Urothelial carcinoma Metastatic non-small cell lung cancer 761041 Link avelumab Bavencio EMD Serono 3/23/2017 intravenous fully human PD-L1 Metastatic...
    57 KB (4,072 words) - 11:12, 5 August 2024
  • collaboration with Pfizer to evaluate combination of Bempegaldesleukin with avelumab and talazoparib or enzalutamide in multiple cancers. In March 2022 it was...
    7 KB (599 words) - 00:43, 16 August 2023
  • studied. Dostarlimab exhibits better efficacy than PD-L1 inhibitors, such as avelumab and durvalumab, in dMMR advanced endometrial cancers. Efficacy of the drug...
    37 KB (3,213 words) - 06:55, 8 August 2024
  • Necitumumab L01FF01 Nivolumab L01FF02 Pembrolizumab L01FF03 Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab...
    12 KB (877 words) - 15:36, 25 January 2024
  • Palbociclib (CDK4/6 inhibitor), Fulvestrant (estrogen receptor antagonist), and Avelumab (monoclonal antibody) for the treatment of metastatic ER+ HER- breast cancer...
    24 KB (2,633 words) - 00:57, 22 April 2024
  • with metastatic bladder cancer who are receiving chemotherapy followed by avelumab. Rintodestrant, an oral selective estrogen receptor degrader (SERD), is...
    20 KB (2,065 words) - 01:40, 29 December 2023
  • refractory to PD-L1 or PD-1 therapies such as pembrolizumab, nivolumab, avelumab) Second-line HNSCC In each of the three indications, a first cohort of...
    20 KB (2,722 words) - 14:27, 18 September 2024
  • A.; Uemura, Motohide; Pal, Sumanta K.; Alekseev, Boris (2020-09-07). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker...
    25 KB (2,535 words) - 09:22, 8 April 2023
  • in a Phase Ib/II clinical trial evaluating TG4001 in combination with avelumab (in collaboration with Merck KGaA and Pfizer) in patients with advanced...
    13 KB (1,178 words) - 21:27, 3 September 2024
  • Thumbnail for CKLF like MARVEL transmembrane domain containing 6
    antibody drugs, e.g. pembrolizumab, atezolizumab, durvalumab nivolumab, and avelumab, bind to and inhibit the stimulation of PD-1 on CD8+ T cells by PD-L1....
    11 KB (1,412 words) - 07:13, 25 June 2024
  • PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. (November 2020). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker...
    13 KB (1,146 words) - 19:53, 6 February 2024
  • (Gemtuzumab ozogamicin) Other Amivantamab Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab...
    12 KB (758 words) - 23:46, 14 March 2024
  • Thumbnail for Andrea Apolo
    in cancer and genitourinary tumors. She led the bladder cancer study of avelumab that resulted in FDA approval in advanced bladder cancer. Apolo received...
    5 KB (449 words) - 05:07, 9 August 2024
  • cancer, he is developing immune therapy in ovarian cancer and studies avelumab and nivolumab alone or in combination. While discussing COVID-19 and ovarian...
    28 KB (3,247 words) - 04:38, 28 July 2024
  • Human Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab...
    2 KB (87 words) - 01:28, 30 May 2023